Homepage
Author:
Telix Pharmaceuticals Limited
Posted Date:
May 4, 2026
New Publication Demonstrates TLX250-Px (Zircaix®) Potential in Diagnosing Kidney Cancers Beyond ccRCC
Telix Pharmaceuticals Limited
May 4, 2026
TLX101-Px (Pixlumi®) MAA Accepted in Europe
Telix Pharmaceuticals Limited
April 30, 2026
OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer
Telix Pharmaceuticals Limited
April 29, 2026
Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach
Telix Pharmaceuticals Limited
April 27, 2026
ProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026
Telix Pharmaceuticals Limited
April 21, 2026
Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma
Telix Pharmaceuticals Limited
April 14, 2026
Telix and Regeneron Announce Strategic Radiopharma Collaboration
Telix Pharmaceuticals Limited
April 13, 2026
Telix Strengthens Board with Additional Director Appointments
Telix Pharmaceuticals Limited
April 8, 2026
Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement
Telix Pharmaceuticals Limited
April 7, 2026
Telix Appoints David Gill as Non-Executive Director
Telix Pharmaceuticals Limited
April 1, 2026
1
2
Next
